Search research articles
Contact Us
Filters
Showing results (811-820 of 848) with videos related to
Page
of 85
Sort By:
Blood
|
August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Xin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
NEJM Evidence
|
February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
Michael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
British Journal of Haematology
|
November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Thomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W Press, Hongli Li, Heiko Schöder, et al.
Blood
|
September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Anthony R Mato, Chadi Nabhan, Paul M Barr, et al.
Leukemia
|
June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J R Brown, P Hillmen, S O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
The New England Journal of Medicine
|
December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Jan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
Page
of 85
Search research articles
Search
Showing results (811-820 of 848) with videos related to
Sort By:
Page
of 85
Blood
|
August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Xin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
NEJM Evidence
|
February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers
Michael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
British Journal of Haematology
|
November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia
Toby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Thomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W Press, Hongli Li, Heiko Schöder, et al.
Blood
|
September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Anthony R Mato, Chadi Nabhan, Paul M Barr, et al.
Leukemia
|
June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J R Brown, P Hillmen, S O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
The New England Journal of Medicine
|
December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Jan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
Page
of 85